Eledon Pharmaceuticals (ELDN) Change in Cash (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Change in Cash data on file, last reported at -$16.7 million in Q1 2026.

• Quarterly Change in Cash fell 38.19% year-over-year to -$16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 million (down 182.51% YoY) and the FY2025 annual result came in at $2.3 million, down 85.83% from the prior year.
• Change in Cash declined to -$16.7 million in Q1 2026, from $19.1 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $20.4 million in Q2 2024 to a low of -$37.3 million in Q3 2023.
• A 5-year average of -$4.6 million and a median of -$5.5 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash jumped 1360.11% — and 2025, when it slumped 1255.61%.
• Tracing ELDN's Change in Cash over 5 years: stood at -$9.5 million in 2022, then jumped by 109.97% to $945000.0 in 2023, then jumped by 1360.11% to $13.8 million in 2024, then surged by 38.71% to $19.1 million in 2025, then sank by 187.03% to -$16.7 million in 2026.
• The last three Change in Cash figures came in at -$16.7 million (Q1 2026), $19.1 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.